We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...

Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to a Reuters report.

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other stocks that Jim Cramer discussed. On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave ...

WuXi Biologics is a leading global CRDMO, with the R represented by our premium-quality CRO Services. With expertise in diverse drug modalities, we deliver comprehensive research services, including ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

In the latest draft report, WuXi Biologics was also added to the list of named companies that are considered of concern. In the last six months, WuXi Biologics’ share price has fallen by over 70 ...